Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02115399 · ClinicalTrials.gov registry record

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
150
Enrollment target

NCT02115399 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02115399 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
150 participants
Enrollment target

Study Summary

The purpose of this study is to look at how defects in the skin barrier and immune response affect risk for skin infections. Participants will be classified into 4 groups based on Atopic Dermatitis (AD)/Non-Atopic (NA) status and Staphylococcus aureus (S. aureus) colonization (negative or positive): * AD S. aureus negative * AD S. aureus positive * NA S. aureus negative and * NA S. aureus positive.

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2014-04
Est. Completion 2015-06

What the Registry Record Tells You About NCT02115399

The ClinicalTrials.gov registry entry for NCT02115399 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02115399 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02115399 about?

NCT02115399 is a clinical study titled "ADRN Barrier/Immunoprofiling Exploratory Pilot Study". The purpose of this study is to look at how defects in the skin barrier and immune response affect risk for skin infections. Participants will be classified into 4 groups based on Atopic Dermatitis (AD)/Non-Atopic (NA) status and Staphylococcus aureus (S. aureus) colonization (negative or positive)...

What is the current status of trial NCT02115399?

This trial is currently completed. The enrollment target is 150 participants. The study started on 2014-04. Estimated completion is 2015-06.

Who is sponsoring clinical trial NCT02115399?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.